mTOR inhibitors such as rapamycin and its analogs (temsirolimus, everolimus, and deforolimus) stimulate autophagy and exhibit anti-tumor activity in multiple hematological malignancies including AML, MCL, and MM [351,352,353], while AMPK activators like metformin [354] and AICAR [355] suppress proliferation and induce apoptosis through autophagy activation among other mechanisms [349,354,356,357]. The gene discussed is MTOR; the disease is hematologic disorder.